

2019 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES

Pasadena, CA – April 27, 2019

| | | |
|----------------------------|---|--|
| Conference Location | Sheraton Pasadena Hotel 303 Cordova St. Pasadena, CA 91101 | Phone: (626) 449-4000 https://www.marriott.com/hotels/travel/laxsp-sheraton-pasadena-hotel |
|----------------------------|---|--|

Parking at the Conference Reduced parking for all participants is available for \$15. Street parking and nearby lots are also available

From US-101 S/(Ventura Fwy) OR US 5 (Golden State Fwy) and CA-134 E (Pasadena Fwy):

Driving Directions

- Continue on CA-134 E, follow signs for Burbank/Pasadena
- Take exit 25C for Fair Oaks Ave toward Marengo Ave
- Merge onto Corson Street
- Turn Left at Marengo Ave
- The hotel will be on the left side just before Cordova St

Seminar Agenda and Syllabus Information

Registration and breakfast begin at **7:30 a.m.** in the **Magnolia Room**. Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. WiFi will be available without charge.

| | |
|-----------------|---|
| 7:30 am | <i>Registration, Continental Breakfast & View Exhibits</i> |
| 8:00am | Opening Comments and Pre-Test |
| 8:20 am | <p>End Stage Liver Disease: Treatment, Managing Complications and Transplant</p> <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease <p>Liver Transplantation</p> <ul style="list-style-type: none"> • Listing Criteria and MELD Exceptions <p>Case Study 1 – Cirrhosis and Encephalopathy</p> |
| 9:20 am | <p>Hepatocellular Carcinoma</p> <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery |
| 10:00 am | <i>Break & View Exhibits</i> |
| 10:15 am | <p>Hepatocellular Carcinoma: New Systemic Treatment Options</p> <ul style="list-style-type: none"> • Currently FDA Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC <p>Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma</p> |
| 11:00 am | Primary Sclerosing Cholangitis (PSC) |

| | |
|-----------------|--|
| | <ul style="list-style-type: none"> • Epidemiology • Ursodiol and Antibiotic Treatments • Predicting Outcomes and Improving Survival |
| 11:25 am | New Treatments for PBC <ul style="list-style-type: none"> • Causes and Markers of PBC • Treatment Management • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid |
| 12:00 pm | <i>Luncheon and Educational Session “LAL-D: Lysosomal Acid Lipase Deficiency- Implementing Rule-out testing in patients with elevated ALT and LDL-C. Hosted by Alexion Pharmaceuticals</i> |
| 1:00 pm | The Best Use of Non-Invasive Imaging for Fibrosis Assessment <ul style="list-style-type: none"> • Technologies, Procedures and Outcomes |
| 1:30 pm | NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology and Demographics • Diagnosis and Evaluation • Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Causing Adult Fatty Liver • Conventional treatments |
| 2:15 pm | <i>Break & View Exhibits</i> |
| 2:25 pm | NASH Treatments in Development <ul style="list-style-type: none"> • Life Style Changes • Drugs in Clinical development for NASH Case Study 3 - NASH Diagnosis and Treatment |
| 3:25 pm | Post-test and Wrap-Up <ul style="list-style-type: none"> • Adjourn at 3:40pm |

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1085. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)[™] organizations accredited by ACCME.

**Your
Seminar
Faculty**



TSE-LING FONG, MD

Dr. Tse-Ling Fong is Associate Professor of Medicine and former Medical Director of the USC Liver Transplantation Program. Dr. Fong obtained his medical degree from the University of Southern California.

A long standing member of American Association for the Study of Liver Disease, he was elected Fellow (inaugural class) in 2014. Since 2002, he has been named every year to “Best Doctors in America” distinction. He has published extensively in chronic hepatitis B, hepatitis C, liver transplantation and drug-induced liver injury.



SAMMY SAAB, MD, MPH

Sammy Saab is a Professor in the Departments of Internal Medicine and Surgery at the David Geffen School of Medicine. He is also Head of Outcomes Research in Hepatology at the Pflieger Liver Institute.

Dr. Saab received his BS, MD, and MPH from UCLA. He completed his residency in internal medicine at University of California at San Diego Medical Center and a fellowship in gastroenterology/hepatology at UCLA Center for Health Sciences. Dr. Saab is board certified in internal medicine, gastroenterology, and transplant hepatology. He has received honorary fellowships from the American Gastroenterology Association (AGAF), American College of Gastroenterology (FACG) and the American Association for the Study of Liver Diseases (FAASLD).



LUCY MATHEW, ACNP-BC

Lucy Mathew is a nationally certified Nurse Practitioner with a Master’s degree in the specialty of Acute Care Nurse Practitioner. She graduated from UCLA in 1998.

For the past fourteen years, she has been working with patients with a variety of liver diseases, specializing in viral hepatitis and cirrhosis. She is an expert in this field and has given many lectures to peers. Lucy is also involved in many clinical trials at Cedars Sinai Medical Center. She has organized nursing symposiums and has been a speaker in many local and national level educational meetings.
